Product Description
a first-in-class compound that targets both EGFR with TGFbeta (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04429542)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Bright Cell, Inc.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Other
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05162326 |
BC101-C01 | P1 |
Not yet recruiting |
Other |
2027-12-30 |
2025-12-30 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/01/2024 |
News Article |
Bauformat Thanks 2024 Vancouver Interior Design Show Attendees |
|
09/27/2024 |
News Article |
Bauformat's Booth at Vancouver Interior Design Show Creates Buzz |
|
09/26/2024 |
News Article |
European Kitchen Cabinets by Bauformat at IDS 2024 |
|
09/24/2024 |
News Article |
Unprecedented 20% Off Bauformat Kitchens & Closets |